Peptides and combination of peptides for use in immunotherapy against various tumors
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
1. A peptide comprising the amino acid sequence of KVWSDVTPL (SEQ ID NO: 24) in the form of a pharmaceutical acceptable salt, wherein said peptide has an overall length of less than 30 amino acids.
2. The peptide according to claim 1 , wherein said peptide has the ability to bind to an MHC class-I or II molecule, and wherein said peptide, when bound to said MHC, is capable of being recognized by CD4 and/or CD8 T cells.
3. The peptide according to claim 1 , wherein the peptide consists of or consists essentially of the amino acid sequence of KVWSDVTPL (SEQ ID NO: 24) in the form of a pharmaceutical acceptable salt.
4. The peptide according to claim 1 , wherein said peptide is modified and/or includes non-peptide bonds.
5. The peptide according to claim 1 , wherein said peptide is part of a fusion protein, and wherein the fusion protein optionally comprises N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii).
6. The peptide according to claim 1 , wherein said peptide has an overall length of from 9 to 15 amino acids.
7. The peptide according to claim 2 , wherein said peptide has an overall length of from 9 to 15 amino acids.